Trial Profile
A Phase 1b/2 Study of PCM-075 (Onvansertib) in Combination With Either Low-Dose Cytarabine or Decitabine in Subjects With Acute Myeloid Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Decitabine (Primary) ; Onvansertib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cardiff Oncology
- 04 Jan 2022 Status changed from active, no longer recruiting to completed.
- 14 Dec 2021 Results identifying molecular predictors of response to the ONV-DAC combinationpresented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 26 May 2021 Planned primary completion date changed from 30 Apr 2021 to 31 Oct 2021.